A Phase 1b Study of Transforming Growth Factor-Beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma

Investigational New Drugs - Netherlands
doi 10.1007/s10637-018-0636-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC